JCM
JAZZ icon

Janney Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Janney Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,000
Closed -$292K – 231
2017
Q3 		$292K Buy
+2,000
New +$302K 0.01% 189

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janney Capital Management's JAZZ Position: Q4 2017 in Review

Janney Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2017, closing a stake of 2,000 shares — an estimated $292K sold.

Janney Capital Management first reported a position in JAZZ in Q3 2017 and held it in 1 quarter. The position peaked at $292K in Q3 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

  • Janney Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Janney Capital Management sold 2,000 Jazz Pharmaceuticals shares in Q4 2017, an estimated $292K.
  • Janney Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Janney Capital Management's Jazz Pharmaceuticals position peaked at $292K in Q3 2017.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on Janney Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.